Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
> 26 27 26 27 O
= 27 28 27 28 O
1500 29 33 29 33 B-lower_bound
/ 33 34 33 34 I-lower_bound
mL 34 36 34 36 I-lower_bound

Active 0 6 37 43 B-chronic_disease
infection 7 16 44 53 I-chronic_disease
requiring 17 26 54 63 O
intravenous 27 38 64 75 B-treatment
( 39 40 76 77 I-treatment
IV 40 42 77 79 I-treatment
) 42 43 79 80 I-treatment
antibiotics 44 55 81 92 I-treatment
or 56 58 93 95 O
other 59 64 96 101 O
uncontrolled 65 77 102 114 O
intercurrent 78 90 115 127 B-chronic_disease
illness 91 98 128 135 I-chronic_disease
requiring 99 108 136 145 O
hospitalization 109 124 146 161 B-treatment

Any 0 3 162 165 O
medical 4 11 166 173 O
condition 12 21 174 183 O
or 22 24 184 186 O
diagnosis 25 34 187 196 O
that 35 39 197 201 O
would 40 45 202 207 O
likely 46 52 208 214 O
impair 53 59 215 221 O
absorption 60 70 222 232 O
of 71 73 233 235 O
an 74 76 236 238 O
orally 77 83 239 245 O
administered 84 96 246 258 O
drug 97 101 259 263 O
( 102 103 264 265 O
e.g. 103 107 265 269 O
gastrectomy 108 119 270 281 B-treatment
, 119 120 281 282 O
ileal 121 126 283 288 B-treatment
bypass 127 133 289 295 I-treatment
, 133 134 295 296 O
chronic 135 142 297 304 B-chronic_disease
diarrhea 143 151 305 313 I-chronic_disease
, 151 152 313 314 O
gastroparesis 153 166 315 328 B-chronic_disease
) 166 167 328 329 O

Aspartate 0 9 330 339 B-clinical_variable
aminotransferase 10 26 340 356 I-clinical_variable
( 27 28 357 358 I-clinical_variable
AST 28 31 358 361 I-clinical_variable
) 31 32 361 362 I-clinical_variable
( 33 34 363 364 O
serum 34 39 364 369 B-clinical_variable
glutamic 40 48 370 378 I-clinical_variable
oxaloacetic 49 60 379 390 I-clinical_variable
transaminase 61 73 391 403 I-clinical_variable
[ 74 75 404 405 I-clinical_variable
SGOT 75 79 405 409 I-clinical_variable
] 79 80 409 410 I-clinical_variable
) 80 81 410 411 O
and 82 85 412 415 O
alanine 86 93 416 423 B-treatment
aminotransferase 94 110 424 440 I-treatment
( 111 112 441 442 I-treatment
ALT 112 115 442 445 I-treatment
) 115 116 445 446 I-treatment
( 117 118 447 448 O
serum 118 123 448 453 B-treatment
glutamate 124 133 454 463 I-treatment
pyruvate 134 142 464 472 I-treatment
transaminase 143 155 473 485 I-treatment
[ 156 157 486 487 I-treatment
SGPT 157 161 487 491 I-treatment
] 161 162 491 492 I-treatment
) 162 163 492 493 O
= 164 165 494 495 O
< 165 166 495 496 O
2.5 167 170 497 500 B-upper_bound
x 171 172 501 502 I-upper_bound
ULN 173 176 503 506 I-upper_bound
( 177 178 507 508 O
or 178 180 508 510 O
= 181 182 511 512 O
< 182 183 512 513 O
5 184 185 514 515 O
x 186 187 516 517 O
ULN 188 191 518 521 O
if 192 194 522 524 O
liver 195 200 525 530 B-cancer
metastases 201 211 531 541 I-cancer
[ 212 213 542 543 I-cancer
mets 213 217 543 547 I-cancer
] 217 218 547 548 I-cancer
) 218 219 548 549 I-cancer

Eastern 0 7 550 557 B-clinical_variable
Cooperative 8 19 558 569 I-clinical_variable
Oncology 20 28 570 578 I-clinical_variable
Group 29 34 579 584 I-clinical_variable
( 35 36 585 586 I-clinical_variable
ECOG 36 40 586 590 I-clinical_variable
) 40 41 590 591 I-clinical_variable
performance 42 53 592 603 I-clinical_variable
status 54 60 604 610 I-clinical_variable
( 61 62 611 612 I-clinical_variable
PS 62 64 612 614 I-clinical_variable
) 64 65 614 615 I-clinical_variable
0 66 67 616 617 B-lower_bound
- 67 68 617 618 O
1 68 69 618 619 B-upper_bound

Has 0 3 620 623 O
a 4 5 624 625 O
known 6 11 626 631 O
additional 12 22 632 642 O
malignancy 23 33 643 653 B-cancer
that 34 38 654 658 O
is 39 41 659 661 O
progressing 42 53 662 673 O
or 54 56 674 676 O
requires 57 65 677 685 O
active 66 72 686 692 B-treatment
treatment 73 82 693 702 I-treatment
; 82 83 702 703 O
exceptions 84 94 704 714 O
include 95 102 715 722 O
basal 103 108 723 728 B-cancer
cell 109 113 729 733 I-cancer
carcinoma 114 123 734 743 I-cancer
of 124 126 744 746 I-cancer
the 127 130 747 750 I-cancer
skin 131 135 751 755 I-cancer
, 135 136 755 756 O
squamous 137 145 757 765 B-cancer
cell 146 150 766 770 I-cancer
carcinoma 151 160 771 780 I-cancer
of 161 163 781 783 I-cancer
the 164 167 784 787 I-cancer
skin 168 172 788 792 I-cancer
that 173 177 793 797 O
has 178 181 798 801 O
undergone 182 191 802 811 O
potentially 192 203 812 823 O
curative 204 212 824 832 B-treatment
therapy 213 220 833 840 I-treatment
or 221 223 841 843 O
in 224 226 844 846 B-cancer
situ 227 231 847 851 I-cancer
cervical 232 240 852 860 I-cancer
cancer 241 247 861 867 I-cancer

Has 0 3 868 871 O
a 4 5 872 873 O
known 6 11 874 879 O
psychiatric 12 23 880 891 B-chronic_disease
or 24 26 892 894 I-chronic_disease
substance 27 36 895 904 I-chronic_disease
abuse 37 42 905 910 I-chronic_disease
disorders 43 52 911 920 I-chronic_disease
that 53 57 921 925 O
would 58 63 926 931 O
interfere 64 73 932 941 O
with 74 78 942 946 O
cooperation 79 90 947 958 O
with 91 95 959 963 O
the 96 99 964 967 O
requirements 100 112 968 980 O
of 113 115 981 983 O
the 116 119 984 987 O
trial 120 125 988 993 O

Has 0 3 994 997 O
known 4 9 998 1003 O
active 10 16 1004 1010 O
central 17 24 1011 1018 B-cancer
nervous 25 32 1019 1026 I-cancer
system 33 39 1027 1033 I-cancer
( 40 41 1034 1035 I-cancer
CNS 41 44 1035 1038 I-cancer
) 44 45 1038 1039 I-cancer
metastases 46 56 1040 1050 I-cancer
and/or 57 63 1051 1057 O
carcinomatous 64 77 1058 1071 B-cancer
meningitis 78 88 1072 1082 I-cancer
; 88 89 1082 1083 O
subjects 90 98 1084 1092 O
with 99 103 1093 1097 O
previously 104 114 1098 1108 O
treated 115 122 1109 1116 O
brain 123 128 1117 1122 B-cancer
metastases 129 139 1123 1133 I-cancer
may 140 143 1134 1137 O
participate 144 155 1138 1149 O
provided 156 164 1150 1158 O
they 165 169 1159 1163 O
are 170 173 1164 1167 O
stable 174 180 1168 1174 O
( 181 182 1175 1176 O
without 182 189 1176 1183 O
evidence 190 198 1184 1192 O
of 199 201 1193 1195 O
progression 202 213 1196 1207 O
by 214 216 1208 1210 O
imaging 217 224 1211 1218 O
for 225 228 1219 1222 O
at 229 231 1223 1225 O
least 232 237 1226 1231 O
four 238 242 1232 1236 B-lower_bound
weeks 243 248 1237 1242 I-lower_bound
prior 249 254 1243 1248 I-lower_bound
to 255 257 1249 1251 O
the 258 261 1252 1255 O
first 262 267 1256 1261 B-treatment
dose 268 272 1262 1266 I-treatment
of 273 275 1267 1269 I-treatment
trial 276 281 1270 1275 I-treatment
treatment 282 291 1276 1285 I-treatment
and 292 295 1286 1289 O
any 296 299 1290 1293 O
neurologic 300 310 1294 1304 O
symptoms 311 319 1305 1313 O
have 320 324 1314 1318 O
returned 325 333 1319 1327 O
to 334 336 1328 1330 O
baseline 337 345 1331 1339 O
) 345 346 1339 1340 O
, 346 347 1340 1341 O
have 348 352 1342 1346 O
no 353 355 1347 1349 O
evidence 356 364 1350 1358 O
of 365 367 1359 1361 O
new 368 371 1362 1365 O
or 372 374 1366 1368 O
enlarging 375 384 1369 1378 O
brain 385 390 1379 1384 O
metastases 391 401 1385 1395 O
, 401 402 1395 1396 O
and 403 406 1397 1400 O
are 407 410 1401 1404 O
not 411 414 1405 1408 O
using 415 420 1409 1414 O
steroids 421 429 1415 1423 B-treatment
for 430 433 1424 1427 O
at 434 436 1428 1430 O
least 437 442 1431 1436 O
7 443 444 1437 1438 B-lower_bound
days 445 449 1439 1443 I-lower_bound
prior 450 455 1444 1449 I-lower_bound
to 456 458 1450 1452 O
trial 459 464 1453 1458 O
treatment 465 474 1459 1468 O
; 474 475 1468 1469 O
this 476 480 1470 1474 O
exception 481 490 1475 1484 O
does 491 495 1485 1489 O
not 496 499 1490 1493 O
include 500 507 1494 1501 O
carcinomatous 508 521 1502 1515 O
meningitis 522 532 1516 1526 O
which 533 538 1527 1532 O
is 539 541 1533 1535 O
excluded 542 550 1536 1544 O
regardless 551 561 1545 1555 O
or 562 564 1556 1558 O
clinical 565 573 1559 1567 O
stability 574 583 1568 1577 O

Hemoglobin 0 10 1578 1588 B-clinical_variable
> 11 12 1589 1590 O
= 12 13 1590 1591 O
9 14 15 1592 1593 B-lower_bound
g 16 17 1594 1595 I-lower_bound
/ 17 18 1595 1596 I-lower_bound
dL 18 20 1596 1598 I-lower_bound
( 21 22 1599 1600 O
or 22 24 1600 1602 O
> 25 26 1603 1604 O
= 26 27 1604 1605 O
5.6 28 31 1606 1609 B-lower_bound
mmol 32 36 1610 1614 I-lower_bound
/ 36 37 1614 1615 I-lower_bound
L 37 38 1615 1616 I-lower_bound
) 38 39 1616 1617 O

History 0 7 1618 1625 O
of 8 10 1626 1628 O
cerebrovascular 11 26 1629 1644 B-chronic_disease
accident 27 35 1645 1653 I-chronic_disease
( 36 37 1654 1655 I-chronic_disease
CVA 37 40 1655 1658 I-chronic_disease
) 40 41 1658 1659 I-chronic_disease
, 41 42 1659 1660 O
myocardial 43 53 1661 1671 B-chronic_disease
infarction 54 64 1672 1682 I-chronic_disease
or 65 67 1683 1685 O
unstable 68 76 1686 1694 B-chronic_disease
angina 77 83 1695 1701 I-chronic_disease
within 84 90 1702 1708 O
the 91 94 1709 1712 O
previous 95 103 1713 1721 B-upper_bound
6 104 105 1722 1723 I-upper_bound
months 106 112 1724 1730 I-upper_bound
before 113 119 1731 1737 O
starting 120 128 1738 1746 O
therapy 129 136 1747 1754 B-treatment

International 0 13 1755 1768 B-clinical_variable
normalized 14 24 1769 1779 I-clinical_variable
ratio 25 30 1780 1785 I-clinical_variable
( 31 32 1786 1787 I-clinical_variable
INR 32 35 1787 1790 I-clinical_variable
) 35 36 1790 1791 I-clinical_variable
or 37 39 1792 1794 O
prothrombin 40 51 1795 1806 B-clinical_variable
time 52 56 1807 1811 I-clinical_variable
( 57 58 1812 1813 I-clinical_variable
PT 58 60 1813 1815 I-clinical_variable
) 60 61 1815 1816 I-clinical_variable
= 62 63 1817 1818 O
< 63 64 1818 1819 O
1.5 65 68 1820 1823 B-upper_bound
x 69 70 1824 1825 I-upper_bound
ULN 71 74 1826 1829 I-upper_bound
unless 75 81 1830 1836 O
subject 82 89 1837 1844 O
is 90 92 1845 1847 O
receiving 93 102 1848 1857 O
anticoagulant 103 116 1858 1871 B-treatment
therapy 117 124 1872 1879 I-treatment
as 125 127 1880 1882 O
long 128 132 1883 1887 O
as 133 135 1888 1890 O
PT 136 138 1891 1893 B-treatment
or 139 141 1894 1896 I-treatment
partial 142 149 1897 1904 I-treatment
thromboplastin 150 164 1905 1919 I-treatment
time 165 169 1920 1924 I-treatment
( 170 171 1925 1926 I-treatment
PTT 171 174 1926 1929 I-treatment
) 174 175 1929 1930 I-treatment
is 176 178 1931 1933 O
within 179 185 1934 1940 O
therapeutic 186 197 1941 1952 O
range 198 203 1953 1958 O
of 204 206 1959 1961 O
intended 207 215 1962 1970 O
use 216 219 1971 1974 O
of 220 222 1975 1977 O
anticoagulants 223 237 1978 1992 B-treatment
; 237 238 1992 1993 O
activated 239 248 1994 2003 B-clinical_variable
PTT 249 252 2004 2007 I-clinical_variable
( 253 254 2008 2009 I-clinical_variable
aPTT 254 258 2009 2013 I-clinical_variable
) 258 259 2013 2014 I-clinical_variable
= 260 261 2015 2016 O
< 261 262 2016 2017 O
1.5 263 266 2018 2021 O
x 267 268 2022 2023 O
ULN 269 272 2024 2027 O
unless 273 279 2028 2034 O
subject 280 287 2035 2042 O
is 288 290 2043 2045 O
receiving 291 300 2046 2055 O
anticoagulant 301 314 2056 2069 O
therapy 315 322 2070 2077 O
as 323 325 2078 2080 O
long 326 330 2081 2085 O
as 331 333 2086 2088 O
PT 334 336 2089 2091 O
or 337 339 2092 2094 O
PTT 340 343 2095 2098 O
is 344 346 2099 2101 O
within 347 353 2102 2108 O
therapeutic 354 365 2109 2120 O
range 366 371 2121 2126 O
of 372 374 2127 2129 O
intended 375 383 2130 2138 O
use 384 387 2139 2142 O
of 388 390 2143 2145 O
anticoagulants 391 405 2146 2160 O

Known 0 5 2161 2166 O
hepatitis 6 15 2167 2176 B-chronic_disease
B 16 17 2177 2178 I-chronic_disease
, 17 18 2178 2179 O
hepatitis 19 28 2180 2189 B-chronic_disease
C 29 30 2190 2191 I-chronic_disease
or 31 33 2192 2194 O
human 34 39 2195 2200 B-chronic_disease
immunodeficiency 40 56 2201 2217 I-chronic_disease
virus 57 62 2218 2223 I-chronic_disease
( 63 64 2224 2225 I-chronic_disease
HIV 64 67 2225 2228 I-chronic_disease
) 67 68 2228 2229 I-chronic_disease
infection 69 78 2230 2239 I-chronic_disease

Patients 0 8 2240 2248 O
must 9 13 2249 2253 O
be 14 16 2254 2256 O
> 17 18 2257 2258 O
= 18 19 2258 2259 O
4 20 21 2260 2261 B-lower_bound
weeks 22 27 2262 2267 I-lower_bound
beyond 28 34 2268 2274 O
treatment 35 44 2275 2284 B-treatment
with 45 49 2285 2289 I-treatment
any 50 53 2290 2293 I-treatment
chemotherapy 54 66 2294 2306 I-treatment
or 67 69 2307 2309 I-treatment
other 70 75 2310 2315 I-treatment
investigational 76 91 2316 2331 I-treatment
therapy 92 99 2332 2339 I-treatment
to 100 102 2340 2342 I-treatment
include 103 110 2343 2350 I-treatment
hormonal 111 119 2351 2359 I-treatment
, 119 120 2359 2360 I-treatment
biological 121 131 2361 2371 I-treatment
, 131 132 2371 2372 I-treatment
or 133 135 2373 2375 I-treatment
targeted 136 144 2376 2384 I-treatment
agents 145 151 2385 2391 I-treatment
; 151 152 2391 2392 O
or 153 155 2393 2395 O
at 156 158 2396 2398 O
least 159 164 2399 2404 O
5 165 166 2405 2406 B-lower_bound
half 167 171 2407 2411 I-lower_bound
- 171 172 2411 2412 I-lower_bound
lives 172 177 2412 2417 I-lower_bound
from 178 182 2418 2422 O
hormonal 183 191 2423 2431 O
, 191 192 2431 2432 O
biological 193 203 2433 2443 O
, 203 204 2443 2444 O
or 205 207 2445 2447 O
targeted 208 216 2448 2456 O
agents 217 223 2457 2463 O
, 223 224 2463 2464 O
whichever 225 234 2465 2474 O
is 235 237 2475 2477 O
shorter 238 245 2478 2485 O
at 246 248 2486 2488 O
the 249 252 2489 2492 O
time 253 257 2493 2497 O
of 258 260 2498 2500 O
treatment 261 270 2501 2510 O
initiation 271 281 2511 2521 O

Patients 0 8 2522 2530 O
must 9 13 2531 2535 O
have 14 18 2536 2540 O
one 19 22 2541 2544 O
of 23 25 2545 2547 O
the 26 29 2548 2551 O
following 30 39 2552 2561 O
: 39 40 2561 2562 O
somatic 41 48 2563 2570 O
mutations 49 58 2571 2580 O
or 59 61 2581 2583 O
deletions 62 71 2584 2593 O
in 72 74 2594 2596 O
BRCA1 75 80 2597 2602 O
or 81 83 2603 2605 O
BRCA2 84 89 2606 2611 O
; 89 90 2611 2612 O
genomic 91 98 2613 2620 O
alterations 99 110 2621 2632 O
in 111 113 2633 2635 O
other 114 119 2636 2641 O
BRCA 120 124 2642 2646 O
pathway 125 132 2647 2654 O
genes 133 138 2655 2660 O
( 139 140 2661 2662 O
subcohorts 140 150 2662 2672 O
: 150 151 2672 2673 O
a. 152 154 2674 2676 O
ATM 155 158 2677 2680 O
, 158 159 2680 2681 O
b. 160 162 2682 2684 O
PALB2 163 168 2685 2690 O
, 168 169 2690 2691 O
c. 170 172 2692 2694 O
other 173 178 2695 2700 O
genes 179 184 2701 2706 O
, 184 185 2706 2707 O
e.g. 186 190 2708 2712 O
Fanconi 191 198 2713 2720 B-chronic_disease
Anemia 199 205 2721 2727 I-chronic_disease
genes 206 211 2728 2733 O
, 211 212 2733 2734 O
ARID1A 213 219 2735 2741 O
, 219 220 2741 2742 O
MER11 221 226 2743 2748 O
, 226 227 2748 2749 O
RAD50 228 233 2750 2755 O
, 233 234 2755 2756 O
NBS1 235 239 2757 2761 O
, 239 240 2761 2762 O
ATR 241 244 2763 2766 O
; 244 245 2766 2767 O
amplification 246 259 2768 2781 O
of 260 262 2782 2784 O
EMSY 263 267 2785 2789 O
) 267 268 2789 2790 O
; 268 269 2790 2791 O
or 270 272 2792 2794 O
germline 273 281 2795 2803 O
mutation 282 290 2804 2812 O
in 291 293 2813 2815 O
BRCA1 294 299 2816 2821 O
or 300 302 2822 2824 O
BRCA 303 307 2825 2829 O
2 308 309 2830 2831 O
( 310 311 2832 2833 O
not 311 314 2833 2836 O
breast 315 321 2837 2843 B-cancer
or 322 324 2844 2846 O
ovarian 325 332 2847 2854 B-cancer
cancer 333 339 2855 2861 I-cancer
) 339 340 2861 2862 O

Patients 0 8 2863 2871 O
who 9 12 2872 2875 O
are 13 16 2876 2879 O
pregnant 17 25 2880 2888 B-pregnancy

Patients 0 8 2889 2897 O
with 9 13 2898 2902 O
advanced 14 22 2903 2911 B-cancer
or 23 25 2912 2914 O
metastatic 26 36 2915 2925 B-cancer
cancer 37 43 2926 2932 I-cancer
that 44 48 2933 2937 O
is 49 51 2938 2940 O
refractory 52 62 2941 2951 O
to 63 65 2952 2954 O
standard 66 74 2955 2963 B-treatment
therapy 75 82 2964 2971 I-treatment
or 83 85 2972 2974 O
has 86 89 2975 2978 O
relapsed 90 98 2979 2987 O
after 99 104 2988 2993 O
standard 105 113 2994 3002 O
therapy 114 121 3003 3010 O

Platelets 0 9 3011 3020 B-clinical_variable
> 10 11 3021 3022 O
= 11 12 3022 3023 O
100,000 13 20 3024 3031 B-lower_bound
/ 20 21 3031 3032 I-lower_bound
mL 21 23 3032 3034 I-lower_bound

Prior 0 5 3035 3040 B-treatment
treatment 6 15 3041 3050 I-treatment
with 16 20 3051 3055 I-treatment
a 21 22 3056 3057 I-treatment
PARP 23 27 3058 3062 I-treatment
inhibitor 28 37 3063 3072 I-treatment

Serum 0 5 3073 3078 B-clinical_variable
creatinine 6 16 3079 3089 I-clinical_variable
= 17 18 3090 3091 O
< 18 19 3091 3092 O
1.5 20 23 3093 3096 B-upper_bound
x 24 25 3097 3098 I-upper_bound
upper 26 31 3099 3104 I-upper_bound
limit 32 37 3105 3110 I-upper_bound
of 38 40 3111 3113 I-upper_bound
normal 41 47 3114 3120 I-upper_bound
( 48 49 3121 3122 I-upper_bound
ULN 49 52 3122 3125 I-upper_bound
) 52 53 3125 3126 I-upper_bound
( 54 55 3127 3128 O
or 55 57 3128 3130 O
glomerular 58 68 3131 3141 B-clinical_variable
filtration 69 79 3142 3152 I-clinical_variable
rate 80 84 3153 3157 I-clinical_variable
[ 85 86 3158 3159 I-clinical_variable
GFR 86 89 3159 3162 I-clinical_variable
] 89 90 3162 3163 I-clinical_variable
> 91 92 3164 3165 O
= 92 93 3165 3166 O
60 94 96 3167 3169 B-lower_bound
ml 97 99 3170 3172 I-lower_bound
/ 99 100 3172 3173 I-lower_bound
min 100 103 3173 3176 I-lower_bound
for 104 107 3177 3180 O
patients 108 116 3181 3189 O
with 117 121 3190 3194 O
creatinine 122 132 3195 3205 O
> 133 134 3206 3207 O
1.5 135 138 3208 3211 B-lower_bound
x 139 140 3212 3213 I-lower_bound
ULN 141 144 3214 3217 I-lower_bound
) 144 145 3217 3218 O

Serum 0 5 3219 3224 B-clinical_variable
total 6 11 3225 3230 I-clinical_variable
bilirubin 12 21 3231 3240 I-clinical_variable
= 22 23 3241 3242 O
< 23 24 3242 3243 O
1.5 25 28 3244 3247 O
x 29 30 3248 3249 O
ULN 31 34 3250 3253 O
( 35 36 3254 3255 O
direct 36 42 3255 3261 B-clinical_variable
bilirubin 43 52 3262 3271 I-clinical_variable
= 53 54 3272 3273 O
< 54 55 3273 3274 O
ULN 56 59 3275 3278 O
if 60 62 3279 3281 O
total 63 68 3282 3287 B-clinical_variable
bilirubin 69 78 3288 3297 I-clinical_variable
[ 79 80 3298 3299 I-clinical_variable
bili 80 84 3299 3303 I-clinical_variable
] 84 85 3303 3304 I-clinical_variable
> 86 87 3305 3306 O
1.5 88 91 3307 3310 O
x 92 93 3311 3312 O
ULN 94 97 3313 3316 O
) 97 98 3316 3317 O

Women 0 5 3318 3323 B-gender
of 6 8 3324 3326 O
child 9 14 3327 3332 O
- 14 15 3332 3333 O
bearing 15 22 3333 3340 O
potential 23 32 3341 3350 O
MUST 33 37 3351 3355 O
have 38 42 3356 3360 O
a 43 44 3361 3362 O
negative 45 53 3363 3371 B-pregnancy
serum 54 59 3372 3377 I-pregnancy
or 60 62 3378 3380 I-pregnancy
urine 63 68 3381 3386 I-pregnancy
human 69 74 3387 3392 I-pregnancy
chorionic 75 84 3393 3402 I-pregnancy
gonadotropin 85 97 3403 3415 I-pregnancy
( 98 99 3416 3417 I-pregnancy
HCG 99 102 3417 3420 I-pregnancy
) 102 103 3420 3421 I-pregnancy
test 104 108 3422 3426 O
unless 109 115 3427 3433 O
prior 116 121 3434 3439 B-treatment
tubal 122 127 3440 3445 I-treatment
ligation 128 136 3446 3454 I-treatment
( 137 138 3455 3456 O
> 138 139 3456 3457 O
= 139 140 3457 3458 O
1 141 142 3459 3460 B-lower_bound
year 143 147 3461 3465 I-lower_bound
before 148 154 3466 3472 O
screening 155 164 3473 3482 O
) 164 165 3482 3483 O
, 165 166 3483 3484 O
total 167 172 3485 3490 B-treatment
hysterectomy 173 185 3491 3503 I-treatment
or 186 188 3504 3506 O
menopause 189 198 3507 3516 O
( 199 200 3517 3518 O
defined 200 207 3518 3525 O
as 208 210 3526 3528 O
12 211 213 3529 3531 O
consecutive 214 225 3532 3543 O
months 226 232 3544 3550 O
of 233 235 3551 3553 O
amenorrhea 236 246 3554 3564 B-chronic_disease
) 246 247 3564 3565 O
; 247 248 3565 3566 O
patients 249 257 3567 3575 O
should 258 264 3576 3582 O
not 265 268 3583 3586 B-pregnancy
become 269 275 3587 3593 I-pregnancy
pregnant 276 284 3594 3602 I-pregnancy
or 285 287 3603 3605 O
breastfeed 288 298 3606 3616 O
while 299 304 3617 3622 O
on 305 307 3623 3625 O
this 308 312 3626 3630 O
study 313 318 3631 3636 O
; 318 319 3636 3637 O
sexually 320 328 3638 3646 O
active 329 335 3647 3653 O
patients 336 344 3654 3662 O
must 345 349 3663 3667 O
agree 350 355 3668 3673 B-contraception_consent
to 356 358 3674 3676 I-contraception_consent
use 359 362 3677 3680 I-contraception_consent
dual 363 367 3681 3685 I-contraception_consent
contraception 368 381 3686 3699 I-contraception_consent
for 382 385 3700 3703 O
the 386 389 3704 3707 O
duration 390 398 3708 3716 O
of 399 401 3717 3719 O
study 402 407 3720 3725 O
participation 408 421 3726 3739 O
and 422 425 3740 3743 O
for 426 429 3744 3747 O
120 430 433 3748 3751 B-upper_bound
days 434 438 3752 3756 I-upper_bound
after 439 444 3757 3762 O
the 445 448 3763 3766 O
last 449 453 3767 3771 O
dose 454 458 3772 3776 O
of 459 461 3777 3779 O
talazoparib 462 473 3780 3791 B-treatment

